SYMBIO PHARMACEUTICALS LIMITED

Press Releases SymBio Pharmaceuticals Limited

Equities

4582

JP3383050006

Delayed Japan Exchange Other stock markets 11:30:00 16/05/2024 am IST			5-day change	1st Jan Change
156 ^JPY	-4.29%		-4.29%	-36.84%

19/04	SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC	CI
18/03	SymBio Pharmaceuticals Limited amended terms of the transaction	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

DelveInsight Evaluates a Robust Adenovirus Infections Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain	16/23/16	AQ
SymBio Pharmaceuticals : Revision to Earnings Forecast for FY 2022	04/22/04	PU
SymBio Pharmaceuticals : Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2022 (Consolidated)	04/22/04	PU
Adenovirus Infections Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight \| Tianjin CanSino Biotechnology, Kuur therapeutics, AlloVir, SymBio Pharmaceuticals and Others.	12/21/12	AQ
Eagle Pharmaceuticals : Japanese Licensing Partner, SymBio, Receives Approval of TREAKISYM Ready-To-Dilute Formulation, with Launch Expected in January 2021	24/20/24	AQ
Eagle Pharmaceuticals : Japanese Licensing Partner SymBio Announces Completion of Clinical Trial Enrollment for TREAKISYM Rapid Infusion Liquid Bendamustine Formulation	31/20/31	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW